Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

By Carrera S.   Buque A.   Azkona E.   Aresti U.   Calvo B.   Sancho A.   Arruti M.   Nuño M.   Rubio I.   Lobera A.   Lopez C.   Vivanco G.  

Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. : 339-350

Springer Publishing Company

Access to resources Recommend Favorite

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396

Spandidos Publications

Access to resources Recommend Favorite

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny

By Suda Kenichi  

Cancer and Metastasis Reviews, Vol. 31, Iss. 3-4, 2012-12 ,pp. : 807-814

Springer Publishing Company

Access to resources Recommend Favorite